765 related articles for article (PubMed ID: 27612592)
1. Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical Use.
Dadhania V; Zhang M; Zhang L; Bondaruk J; Majewski T; Siefker-Radtke A; Guo CC; Dinney C; Cogdell DE; Zhang S; Lee S; Lee JG; Weinstein JN; Baggerly K; McConkey D; Czerniak B
EBioMedicine; 2016 Oct; 12():105-117. PubMed ID: 27612592
[TBL] [Abstract][Full Text] [Related]
2. Assessment of Luminal and Basal Phenotypes in Bladder Cancer.
Guo CC; Bondaruk J; Yao H; Wang Z; Zhang L; Lee S; Lee JG; Cogdell D; Zhang M; Yang G; Dadhania V; Choi W; Wei P; Gao J; Theodorescu D; Logothetis C; Dinney C; Kimmel M; Weinstein JN; McConkey DJ; Czerniak B
Sci Rep; 2020 Jun; 10(1):9743. PubMed ID: 32546765
[TBL] [Abstract][Full Text] [Related]
3. Specific micro-RNA expression patterns distinguish the basal and luminal subtypes of muscle-invasive bladder cancer.
Ochoa AE; Choi W; Su X; Siefker-Radtke A; Czerniak B; Dinney C; McConkey DJ
Oncotarget; 2016 Dec; 7(49):80164-80174. PubMed ID: 27845906
[TBL] [Abstract][Full Text] [Related]
4. Predicting outcomes in non-muscle invasive (Ta/T1) bladder cancer: the role of molecular grade based on luminal/basal phenotype.
Rebola J; Aguiar P; Blanca A; Montironi R; Cimadamore A; Cheng L; Henriques V; Lobato-Faria P; Lopez-Beltran A
Virchows Arch; 2019 Oct; 475(4):445-455. PubMed ID: 31240474
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical based molecular subtypes of muscle-invasive bladder cancer: association with HER2 and EGFR alterations, neoadjuvant chemotherapy response and survival.
Helal DS; Darwish SA; Awad RA; Ali DA; El-Guindy DM
Diagn Pathol; 2023 Feb; 18(1):11. PubMed ID: 36737799
[TBL] [Abstract][Full Text] [Related]
6. Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications.
Hovelson DH; Udager AM; McDaniel AS; Grivas P; Palmbos P; Tamura S; Lazo de la Vega L; Palapattu G; Veeneman B; El-Sawy L; Sadis SE; Morgan TM; Montgomery JS; Weizer AZ; Day KC; Neamati N; Liebert M; Keller ET; Day ML; Mehra R; Tomlins SA
Eur Urol; 2018 Dec; 74(6):741-753. PubMed ID: 30033047
[TBL] [Abstract][Full Text] [Related]
7. Gene Expression Profile of the Clinically Aggressive Micropapillary Variant of Bladder Cancer.
Guo CC; Dadhania V; Zhang L; Majewski T; Bondaruk J; Sykulski M; Wronowska W; Gambin A; Wang Y; Zhang S; Fuentes-Mattei E; Kamat AM; Dinney C; Siefker-Radtke A; Choi W; Baggerly KA; McConkey D; Weinstein JN; Czerniak B
Eur Urol; 2016 Oct; 70(4):611-620. PubMed ID: 26988609
[TBL] [Abstract][Full Text] [Related]
8. Triple-marker immunohistochemical assessment of muscle-invasive bladder cancer: Is there prognostic significance?
Labban M; Najdi J; Mukherji D; Abou-Kheir W; Tabbarah A; El-Hajj A
Cancer Rep (Hoboken); 2021 Apr; 4(2):e1313. PubMed ID: 33538412
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic opportunities in the intrinsic subtypes of muscle-invasive bladder cancer.
McConkey DJ; Choi W; Ochoa A; Siefker-Radtke A; Czerniak B; Dinney CP
Hematol Oncol Clin North Am; 2015 Apr; 29(2):377-94, x-xi. PubMed ID: 25836941
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical assessment of basal and luminal markers in non-muscle invasive urothelial carcinoma of bladder.
Rodriguez Pena MDC; Chaux A; Eich ML; Tregnago AC; Taheri D; Borhan W; Sharma R; Rezaei MK; Netto GJ
Virchows Arch; 2019 Sep; 475(3):349-356. PubMed ID: 31300876
[TBL] [Abstract][Full Text] [Related]
11. A quantitative polymerase chain reaction based method for molecular subtype classification of urinary bladder cancer-Stromal gene expressions show higher prognostic values than intrinsic tumor genes.
Olah C; Hahnen C; Nagy N; Musial J; Varadi M; Nyiro G; Gyorffy B; Hadaschik B; Rawitzer J; Ting S; Sjödahl G; Hoffmann MJ; Reis H; Szarvas T
Int J Cancer; 2022 Mar; 150(5):856-867. PubMed ID: 34536301
[TBL] [Abstract][Full Text] [Related]
12. Intratumoral heterogeneity of surrogate molecular subtypes in urothelial carcinoma in situ of the urinary bladder: implications for prognostic stratification of high-risk non-muscle-invasive bladder cancer.
Garczyk S; Bischoff F; Schneider U; Golz R; von Rundstedt FC; Knüchel R; Degener S
Virchows Arch; 2021 Aug; 479(2):325-335. PubMed ID: 33650041
[TBL] [Abstract][Full Text] [Related]
13. Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays.
Sanchez-Carbayo M; Socci ND; Lozano J; Saint F; Cordon-Cardo C
J Clin Oncol; 2006 Feb; 24(5):778-89. PubMed ID: 16432078
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Power of a Tumor Differentiation Gene Signature for Bladder Urothelial Carcinomas.
Mo Q; Nikolos F; Chen F; Tramel Z; Lee YC; Hayashi K; Xiao J; Shen J; Chan KS
J Natl Cancer Inst; 2018 May; 110(5):448-459. PubMed ID: 29342309
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical Assays for Bladder Cancer Molecular Subtyping: Optimizing Parsimony and Performance of Lund Taxonomy Classifiers.
Hardy CSC; Ghaedi H; Slotman A; Sjödahl G; Gooding RJ; Berman DM; Jackson CL
J Histochem Cytochem; 2022 May; 70(5):357-375. PubMed ID: 35437049
[TBL] [Abstract][Full Text] [Related]
16. Long non-coding RNAs identify a subset of luminal muscle-invasive bladder cancer patients with favorable prognosis.
de Jong JJ; Liu Y; Robertson AG; Seiler R; Groeneveld CS; van der Heijden MS; Wright JL; Douglas J; Dall'Era M; Crabb SJ; van Rhijn BWG; van Kessel KEM; Davicioni E; Castro MAA; Lotan Y; Zwarthoff EC; Black PC; Boormans JL; Gibb EA
Genome Med; 2019 Oct; 11(1):60. PubMed ID: 31619281
[TBL] [Abstract][Full Text] [Related]
17. Expression signature defined by FOXM1-CCNB1 activation predicts disease recurrence in non-muscle-invasive bladder cancer.
Kim SK; Roh YG; Park K; Kang TH; Kim WJ; Lee JS; Leem SH; Chu IS
Clin Cancer Res; 2014 Jun; 20(12):3233-43. PubMed ID: 24714775
[TBL] [Abstract][Full Text] [Related]
18. Development and Application of a Microfluidics-Based Panel in the Basal/Luminal Transcriptional Characterization of Archival Bladder Cancers.
Kim D; Choi Y; Ireland J; Foreman O; Tam RN; Patel R; Schleifman EB; Motlhabi M; French D; Wong CV; Peters E; Molinero L; Raja R; Amler LC; Hampton GM; Lackner MR; Kabbarah O
PLoS One; 2016; 11(11):e0165856. PubMed ID: 27846280
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathologic and Immunohistochemical Study of Combined Small Cell Carcinoma and Urothelial Carcinoma Molecular Subtype.
Xiao GQ; Barrett MM; Yang Q; Unger PD
Pathol Oncol Res; 2019 Jul; 25(3):889-895. PubMed ID: 29249035
[TBL] [Abstract][Full Text] [Related]
20. Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome.
Lindgren D; Frigyesi A; Gudjonsson S; Sjödahl G; Hallden C; Chebil G; Veerla S; Ryden T; Månsson W; Liedberg F; Höglund M
Cancer Res; 2010 May; 70(9):3463-72. PubMed ID: 20406976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
